Table 3.

Response Rates Among 84 Pomalidomide-Treated Patients With Myelofibrosis

Treatment Arm*	All 84 Patients			Among 55 Patients Without Leukocytosis†		Among 29 Patients With Leukocytosis		Among 62 Patients Who Completed 3 Cycles of Treatment
	No.	%	95% CI	No.	%	No.	%	No.	%
Pomalidomide (2 mg/d) + placebo	5 of 22	23	5 to 41	4 of 11	36	1 of 11	9	5 of 13	38
Pomalidomide (2 mg/d) + prednisone	3 of 19	16	0 to 33	3 of 11	27	0 of 8	0	3 of 13	23
Pomalidomide (0.5 mg/d) + prednisone	8 of 22	36	16 to 56	7 of 16	44	1 of 6	17	8 of 20	40
Prednisone	4 of 21	19	2 to 36	3 of 17	18	1 of 4	25	4 of 16	25

NOTE. All responses signified improvement in anemia according to the Internation Working Group for Myelofibrosis Research and Treatment. The Table also outlines additional information on response rates in patients with and without leukocytosis based on significant influence on multivariable analysis (see text). Response rates restricted to patients who have completed three cycles of protocol therapy are also provided.

^*Please see text for treatment dose and schedule for both pomalidomide and prednisone.

^†Leukocytosis was defined as a leukocyte count of > 10 × 10⁹/L.